Evommune (EVMN) Cash from Investing Activities (2024 - 2026)

Evommune (EVMN) has reported Cash from Investing Activities for 3 consecutive years, with -$85.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 732.29% year-over-year to -$85.4 million; the TTM figure through Mar 2026 stood at -$227.8 million (changed N/A YoY), while the FY2025 annual figure was -$115.3 million, down 2787.73% from the prior year.
• Cash from Investing Activities improved to -$85.4 million in Q1 2026 per EVMN's latest filing, from -$122.9 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $13.5 million in Q1 2025 and bottomed at -$122.9 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$57.0 million across 3 years, with a median of -$59.2 million in 2024.
• Annual changes were most pronounced in 2025 — Cash from Investing Activities slumped 271.53% — and 2026, when it tumbled 732.29%.
• Evommune's Cash from Investing Activities stood at -$33.1 million in 2024, then plunged by 271.53% to -$122.9 million in 2025, then soared by 30.55% to -$85.4 million in 2026.
• Business Quant data shows EVMN's Cash from Investing Activities at -$85.4 million in Q1 2026, -$122.9 million in Q4 2025, and $13.5 million in Q1 2025.